Our study findings are consistent with those of the PALOMA clinical trials [17, 18], and add to the existing evidence that CDK4/6 inhibitors, including palbociclib, in combination with ET maintain HRQOL among patients with ABC as reported in a systematic review of 31 clinical trials and 7 real-world studies [22]. Here, CDK4 is linked to aneurysmal bone cyst.